BN006 has the potential to be a far superior treatment as it has...

BN006 has the potential to be a far superior treatment as it has shown to achieve a therapeutic effect without as much immune-system suppression as other treatments, thereby reducing the risk of infection to patients as well as being a more patient-friendly orally-deliverable treatment."

The studies carried-out in 2013 showed that BN006 was efficacious even at the lowest dose tested. In the current experiments Bone Medical will test a lower range of dosages with the aim of confirming the full breadth of BN006’s dose response.

The same 2013 studies also demonstrated that BN006, when taken orally, can be absorbed in the bloodstream at levels correlating with its anti-inflammatory efficacy. The current experiment will more fully characterise BN006’s profile after oral delivery. The current market leader Humira® is given by injection.

The current experiments are expected to be completed by the end of July 2014 with results anticipated in the month following. Positive results from these studies will advance BN006 nearer to the commencement of human clinical trials, a major milestone for this product program.